Back

PregMedNet: Multifaceted Maternal Medication Impacts on Neonatal Complications

Kim, Y.; Maric, I.; Kashiwagi, C.; Han, L.; Chung, P.; Reiss, J.; Butcher, L. D.; Caoili, K. J.; Berson, E.; Xue, L.; Espinosa, C.; James, T.; Shome, S.; Xie, F.; Ghanem, M.; Seong, D.; Chang, A.; Reincke, M.; Mataraso, S.; Shu, C.-H.; Francesco, D. D.; Becker, M.; Kumar, W.; Wong, R.; Gaudilliere, B.; Angst, M.; Shaw, G. M.; Bateman, B.; Stevenson, D.; Prince, L.; Aghaeepour, N.

2025-02-14 pediatrics
10.1101/2025.02.13.25322242 medRxiv
Show abstract

While medication use is common among pregnant women, medication safety remains insufficiently characterized because studies in pregnant women are challenging due to safety concerns. The recent digitization of healthcare databases and advances in computational methods have created new opportunities for large-scale, retrospective drug safety evaluations. Here, we present PregMedNet, a platform that characterizes multifaceted maternal medication effects on neonatal outcomes during pregnancy, covering more than 27,000 drug-disease pairs across 1,152 medications and 24 outcomes. These results encompass known and novel odds ratios (ORs), adjusted ORs, and drug-drug interactions, systematically analyzed using nationwide claims data and an advanced machine learning pipeline. Notably, one of the newly discovered associations was experimentally validated in vivo. This supports the reliability of PregMedNets findings and demonstrates the utility of claims data and machine learning for perinatal medication safety studies. Additionally, potential biological mechanisms underlying the associations were explored using a graph learning method, providing candidate pathways for future mechanistic investigations. We expect that PregMedNet will contribute to advancing maternal medication safety and improving neonatal outcomes by providing extensive, multifaceted drug safety information on this previously underrepresented population.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Science Bulletin
22 papers in training set
Top 0.1%
15.1%
2
Genome Medicine
154 papers in training set
Top 0.6%
8.6%
3
IEEE Journal of Biomedical and Health Informatics
34 papers in training set
Top 0.1%
8.6%
4
Clinical and Translational Science
21 papers in training set
Top 0.1%
7.4%
5
BioData Mining
15 papers in training set
Top 0.1%
5.0%
6
Nature Communications
4913 papers in training set
Top 38%
3.7%
7
Cell Reports Medicine
140 papers in training set
Top 2%
3.1%
50% of probability mass above
8
Scientific Reports
3102 papers in training set
Top 41%
3.1%
9
BMC Medicine
163 papers in training set
Top 2%
2.1%
10
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 29%
1.9%
11
Communications Medicine
85 papers in training set
Top 0.2%
1.9%
12
npj Digital Medicine
97 papers in training set
Top 2%
1.9%
13
Nature Medicine
117 papers in training set
Top 2%
1.7%
14
Clinical Pharmacology & Therapeutics
25 papers in training set
Top 0.3%
1.7%
15
PLOS ONE
4510 papers in training set
Top 53%
1.7%
16
eBioMedicine
130 papers in training set
Top 1%
1.7%
17
Bioinformatics Advances
184 papers in training set
Top 3%
1.5%
18
Science Translational Medicine
111 papers in training set
Top 3%
1.4%
19
Journal of Biomedical Informatics
45 papers in training set
Top 0.9%
1.4%
20
Journal of the American Medical Informatics Association
61 papers in training set
Top 1%
1.3%
21
Genomics, Proteomics & Bioinformatics
171 papers in training set
Top 4%
1.3%
22
Advanced Science
249 papers in training set
Top 15%
1.0%
23
BMC Medical Genomics
36 papers in training set
Top 1%
0.8%
24
Nature Human Behaviour
85 papers in training set
Top 4%
0.8%
25
Patterns
70 papers in training set
Top 2%
0.8%
26
eLife
5422 papers in training set
Top 57%
0.8%
27
Nature Biomedical Engineering
42 papers in training set
Top 2%
0.7%
28
Nature Machine Intelligence
61 papers in training set
Top 3%
0.7%
29
Pharmaceutics
21 papers in training set
Top 0.5%
0.7%
30
Journal of Medical Internet Research
85 papers in training set
Top 5%
0.7%